| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/15/2006 | CN1732910A Chewing tablet of tramado hydrochloride and its preparation method |
| 02/15/2006 | CN1241940C Novel collagen-like protein CLAC, Precursor thereof and genes encoding the same |
| 02/15/2006 | CN1241932C Novel oligosaccharides, preparation method and pharmaceutical composition containing same |
| 02/15/2006 | CN1241921C Fluoro isoflavone containing derivative, monufacturing method and its use |
| 02/15/2006 | CN1241916C Novel acardite compound, its preparation method and medicinal composition containing said compound |
| 02/15/2006 | CN1241915C Prepn process and use of substituted pyrazole compound |
| 02/15/2006 | CN1241909C Carboxylic acid derivatives as IP antagonists |
| 02/15/2006 | CN1241625C Chinese medicine product with functions of detoxifying in 3 days and eliminating withdrawl syndrome |
| 02/15/2006 | CN1241621C Tonic soporific liquid |
| 02/15/2006 | CN1241619C Smoking stopping products and its preparing process |
| 02/15/2006 | CN1241612C Medicine for treating paralysis disease |
| 02/15/2006 | CN1241599C Application of traditional Chinese medicine composition in preparation of medicine for treating depression and anxiety |
| 02/15/2006 | CN1241597C Method for extracting effective matter from North Fructus schisandrae |
| 02/15/2006 | CN1241576C Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/15/2006 | CN1241567C Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 |
| 02/15/2006 | CN1241565C Edaravone medicine composition and preparation thereof |
| 02/14/2006 | US6998503 crystallized as an anhydrous, stoichiometric 1.5 HCl salt; inhibiting or modulating nitric oxide synthesis |
| 02/14/2006 | US6998494 Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives |
| 02/14/2006 | US6998474 used for prevention and/or treatment of pathologies, dysfunctions, disorders or conditions affecting the nervous system |
| 02/14/2006 | US6998416 Cyclic AMP-specific phosphodiesterase inhibitors |
| 02/14/2006 | US6998409 Drugs for treating chronic pain; stereoisomers; chemical synthesis from intermediates; nontoxic |
| 02/14/2006 | US6998405 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
| 02/14/2006 | US6998403 Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia |
| 02/14/2006 | US6998402 7-(1-Acetylpentyl)-5-methyl-2-(4-methylbenzyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one; learning enhancement, concentration power, learning power, memory power; enzyme inhibitors of phosphodiesterase isoenzyme |
| 02/14/2006 | US6998401 Such as 2-(4-amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide which has neuroprotective effects by inducing calcium binding proteins |
| 02/14/2006 | US6998399 cognition activators; prevention of nicotinic receptors dysfunction, central nervous system; Alzheimer's disease, Parkinson's disease, Huntington's chorea, neurodegenerative diseases |
| 02/14/2006 | US6998263 Methods of preparing and using a viral vector library |
| 02/14/2006 | US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist |
| 02/14/2006 | US6998231 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 02/14/2006 | US6997863 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2374643C 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists |
| 02/14/2006 | CA2363145C Oxamic acids and derivatives as thyroid receptor ligands |
| 02/14/2006 | CA2263167C Ether muscarinic antagonists |
| 02/14/2006 | CA2210044C 4-hydroxy-piperidine derivatives |
| 02/14/2006 | CA2178605C Pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors |
| 02/14/2006 | CA2105666C New centrally acting substituted phenylazacycloalkanes |
| 02/12/2006 | CA2476101A1 Extended-release capsules comprising venlafaxine hydrochloride |
| 02/09/2006 | WO2006015124A2 Fused ring heterocycle kinase modulators |
| 02/09/2006 | WO2006014394A1 Modified pyrimidine glucocorticoid receptor modulators |
| 02/09/2006 | WO2006014185A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/09/2006 | WO2006014024A1 Therapeutic agent for psychoneurotic disease |
| 02/09/2006 | WO2006013948A1 Triazole derivative |
| 02/09/2006 | WO2006013873A1 Drugs having cyclooxygenase inhibiting activity |
| 02/09/2006 | WO2006013049A2 Benzyloxy derivatives as maob inhibitors |
| 02/09/2006 | WO2006000158A8 The use of laetispicine for manufacture of pharmaceutical composition |
| 02/09/2006 | WO2005118558A3 Pyrimidine compounds and use thereof |
| 02/09/2006 | WO2005118511A3 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 02/09/2006 | WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58) |
| 02/09/2006 | WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
| 02/09/2006 | WO2005002586A8 Metabolite of quetiapine |
| 02/09/2006 | WO2004112771A8 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060031956 Nucleotide sequences for gene regulation and methods of use thereof |
| 02/09/2006 | US20060030618 Vanilloid receptor ligands and their use in treatments |
| 02/09/2006 | US20060030605 Pharmaceutical compounds |
| 02/09/2006 | US20060030604 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 02/09/2006 | US20060030601 Novel aminopyridine derivatives as mGluR5 antagonists |
| 02/09/2006 | US20060030598 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 02/09/2006 | US20060030593 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/09/2006 | US20060030587 Method of treating attention deficit disorders with d-threo methylphenidate |
| 02/09/2006 | US20060030580 Contacting phenolic piperidines with opioid receptors; analgesics, anticonvulsants, antitussive agents; diarrhea, drug addiction |
| 02/09/2006 | US20060030577 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| 02/09/2006 | US20060030576 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| 02/09/2006 | US20060030573 melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes |
| 02/09/2006 | US20060030561 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma |
| 02/09/2006 | US20060030560 Pyrimidine compounds |
| 02/09/2006 | US20060030558 use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds |
| 02/09/2006 | US20060030548 Methods of using ryanodine antagonists in treating neural injury |
| 02/09/2006 | US20060030546 antiallergen, viricide, herbicide, autoimmune diseases; screening procedure for the identification of enzymes GcpE and LytB inhibitor; 4-hydroxy-3-methyl-2-butenyl 1-pyrophosphate; precursor of higher isoprenoids in 2-methyl-D-erythritol pathway (MEP) |
| 02/09/2006 | US20060030534 Alzheimer's, Parkinson's, multiple sclerosis, schizophrenia, epilepsy, depression and pain |
| 02/09/2006 | US20060030005 C3b/C4b complement receptor-like molecules and uses thereof |
| 02/09/2006 | US20060029990 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 02/09/2006 | US20060029663 Solid formulation |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029586 Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 02/09/2006 | US20060029580 Method for treating a condition with neural progenitor cells derived from whole bone marrow |
| 02/09/2006 | US20060029547 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 02/09/2006 | DE102004034043A1 Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält A solid pharmaceutical composition contains, the mirtazapine |
| 02/09/2006 | DE102004032165A1 Use of plants of the genus Sideritis, their plant parts and/or their extracts for preventing and/or regulating disturbances with altered serotoninergic neurotransmission e.g. depression, pain, eating disorders and climacteric disturbance |
| 02/09/2006 | CA2592044A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 02/09/2006 | CA2587248A1 Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
| 02/09/2006 | CA2576112A1 Piperidine derivatives as histamine h3 receptor ligands |
| 02/09/2006 | CA2576109A1 Novel piperidine derivatives as histamine h3 receptor ligands for treatment of depression |
| 02/09/2006 | CA2576073A1 Novel piperidine derivative for the treatment of depression |
| 02/09/2006 | CA2576028A1 Heterocyclic compounds useful as dpp- iv inhibitors |
| 02/09/2006 | CA2575936A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/09/2006 | CA2575894A1 Dual nk1/nk3 antagonists against schizophrenia |
| 02/09/2006 | CA2575697A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/09/2006 | CA2575555A1 A gastric retained dosage form of gabapentin |
| 02/09/2006 | CA2575340A1 Macrocyclic beta-secretase inhibitors |
| 02/09/2006 | CA2575018A1 Benzyloxy derivatives as maob inhibitors |
| 02/09/2006 | CA2573573A1 Fused ring heterocycle kinase modulators |
| 02/09/2006 | CA2572544A1 Modified pyrimidine glucocorticoid receptor modulators |
| 02/09/2006 | CA2555566A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623984A1 Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt |
| 02/08/2006 | EP1623983A1 Heterocyclic compounds useful as DPP-IV inhibitors |
| 02/08/2006 | EP1623719A1 Alzheimer's disease treatment method |
| 02/08/2006 | EP1623716A1 Soothing combinations of botanical preparations with aromatherapeutic components, their production and use |